Stock Forecast

  Global Blood Therapeutics, Inc. ( GBT) Stock. Should you Buy or Sell?    $ 67.76

-0.22 (-0.33 %)



Global Blood Therapeutics, Inc. Analysis

Updated on 10-09-2022
Symbol GBT
Price $67.76
Beta 0.833
Volume Avg. $3.33 M
Market Cap $4.57 B
52 Week Range $21.65 - $73.02


Global Blood Therapeutics, Inc. opened the day at $67.76 which is -0.33 % on yesterday's close. Global Blood Therapeutics, Inc. has a 52 week high of $73.02 and 52 week low of $21.65, which is a difference of $51.37. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $4.57 B and total net profit is $194749000 which means the company is trading at 23.47 times profit to market capitalization. Theoretically, if you were to buy Global Blood Therapeutics, Inc. for $4.57 B, it would take 15 years to get your money back. Global Blood Therapeutics, Inc. are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.



Price Chart


1 D | All


Financials




Global Blood Therapeutics, Inc. Stock Forecast - Is Global Blood Therapeutics, Inc. a Buy or Sell?


DCF ScoreStrong Buy
ROE ScoreStrong Sell
ROA ScoreNeutral
DE ScoreStrong Buy
PE ScoreStrong Sell
PB ScoreStrong Buy
Overall RecommendationBuy

Growth and Value


PE Ratio -13.784
Dividend Yiel 0.000
Net Profit Margin -1.373


Valuing Global Blood Therapeutics, Inc.


Price Book Value Ratio 37.552 Price To Book Ratio 37.552
Price To Sales Ratio 18.925 Price Earnings Ratio -13.784


How liquid is Global Blood Therapeutics, Inc.


Current Ratio 6.875
Quick Ratio 5.875


Debt


Debt Ratio 0.864 Debt Equity Ratio 6.354
Long Term Debt To Capitalization 0.846 Total Debt To Capitalization 0.848



Latest news about Global Blood Therapeutics, Inc.


Get ready for more merger mania in pharma sector the rest of the year

Pfizer Inc.'s PFE, +0.24% $5.4 billion acquisition of Global Blood Therapeutics Inc. GBT, +0.02% is the latest sign that cash-flush drug makers are ready to jump back into dealmaking.

Date : 09/08/2022

Global Blood (GBT) to be Acquired by Pfizer, Misses on Earnings

Global Blood (GBT) is set to be acquired by Pfizer for around $5.4 billion. The company missed estimates for earnings while beating the same for revenues in the second quarter of 2022.

Date : 09/08/2022

Pfizer is acquiring Global Blood Therapeutics

Pfizer Inc (NYSE: PFE) has executed a definitive merger agreement with Global Blood Therapeutics Inc (NASDAQ: GBT), whereby Pfizer will acquire the biopharmaceutical corporation dedicated to the delivery, development and discovery of life-changing medical treatment, Global Blood Therapeutics, for $5.4 billion, representing $68.50 per GBT share.

Date : 09/08/2022

Pfizer to buy Global Blood Therapeutics for US$5.4bn

Pfizer Inc (NYSE:PFE) is to pay US$5.4bn in cash to acquire sickle cell disease drugmaker Global Blood Therapeutics, Inc (NASDAQ:GBT) (GBT) as the pharma major looks to leverage the booming revenue from its Covid-19 vaccine and treatment. Pfizer will pay US$68.50 per GBT share, which represents a 7.3% premium over Friday's closing price and nearly 43% over Thursday's closing price.

Date : 09/08/2022

Why Global Blood Therapeutics Stock Was Trouncing the Market Today

The blood-disorder specialist sells itself in a deal with an enterprise value of around $5.4 billion.

Date : 08/08/2022





About Global Blood Therapeutics, Inc.


CEO : Dr. Ted Love
Sector : Healthcare
Industry : Biotechnology

Website : https://www.gbt.com

Exchange : NASDAQ Global Select

Description :

Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.


My Newsletter

Sign Up For Updates & Newsletters